Current and planned clinical trials with trastuzumab (Herceptin).
José Baselga
Seminars in Oncology 27 ( 5) 27 -32
41
2000
Clinical trials of single-agent trastuzumab (Herceptin).
José Baselga
Seminars in Oncology 27 ( 5) 20 -26
38
2000
Activated Extracellular Signal-regulated Kinases: Association with Epidermal Growth Factor Receptor/Transforming Growth Factor α Expression in Head and Neck Squamous Carcinoma and Inhibition by Anti-Epidermal Growth Factor Receptor Treatments
Jordi Codony-Servat , Judit Anido , Silvia Sauleda , Robert I. Nicholson
Cancer Research 61 ( 17) 6500 -6510
266
2001
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.
Jordi Codony-Servat , Joan Albanell , Joaquín Arribas , José Baselga
Cancer Research 59 ( 6) 1196 -1201
230
1999
NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer
Gail M. Clinton , Edward J. Keenan , Adam J. Evans , Ana Lluch
Clinical Cancer Research 8 ( 2) 347 -353
293
2002
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
Danny Rischin , Steven D. Averbuch , Roy S. Herbst , Luca Gianni
Clinical Cancer Research 9 ( 6) 2040 -2048
51
2003
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim , Craig H Mermel , Dale Porter , Guo Wei
PMC
3,811
2010
Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies
Martine Piccart-Gebhart , David D.L. Rimm , Nadia Harbeck , Christos Hatzis
San Antonio Breast Cancer Symposium Abstract 2 View
1
2015
Voie de signalisation du REGF et du VEGF au cours du cancer colorectal : on est sur la bonne voie !
Gérard Milano , José Baselga , Jean-Philippe Spano
Bulletin Du Cancer 92 ( 2) 3 -3
2005
EGFR/VEGF signalling pathway in colorectal cancer: the way we are!
Gérard Milano , José Baselga , Jean-Philippe Spano
Bulletin Du Cancer 92 ( 2) 4 -4
2
2005
A review of EGFR targeted therapy.
José Baselga
Clinical advances in hematology & oncology 1 ( 4) 218
7
2003
New therapeutic agents targeting the epidermal growth factor receptor.
José Baselga
Journal of Clinical Oncology 18 ( 21)
61
2000
Targeting the epidermal growth factor receptor: a clinical reality.
José Baselga
Journal of Clinical Oncology 19 ( 18)
81
2001
Targeting Breast Cancer with Care. Meeting
Jean-Jacques Body , José Baselga
Seminars in Oncology 31 ( 5) 1 -57
2004
Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial
Martine Piccart-Gebhart , Michail Ignatiadis , Paolo Nuciforo , Marion M. Maetens
SABCS Abstracts2View™ Portal
2017
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer
Martine Piccart , Debora Fumagalli , José Bines , Marion Procter
British Journal of Cancer 1 -10
2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
Funda Meric-Bernstam , Udai Banerji , Gerald Batist , Elza C de Bruin
NPJ breast cancer 7 ( 1) 44 -44
11
2021
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric , Jordi Rodon , Josep Tabernero , Filip Janku
Journal of Clinical Oncology 36 ( 13) 1291 -1299
144
2018
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M. Hyman , Lillian M. Smyth , Mark T.A. Donoghue , Shannon N. Westin
Journal of Clinical Oncology 35 ( 20) 2251 -2259
243
2017
Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial
Aditya Bardia , Marina Parton , Sherko Kümmel , Laura G. Estévez
Journal of Clinical Oncology 36 ( 31) 3126 -3133
23
2018